Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients Meeting Abstract
| Authors: | Veluswamy, R.; Bhalla, S.; Samstein, R.; Marron, T.; Gomez, J. E.; Doroshow, D. B.; Sabari, J.; Shum, E.; Saxena, A.; Namakydoust, A.; Chachoua, A.; Wisnivesky, J.; Mandeli, J.; Bhardwaj, N.; Hirsch, F. R.; Merad, M.; Reddy, E. |
| Abstract Title: | Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1019 |
| End Page: | S1020 |
| Language: | English |
| ACCESSION: | WOS:000866211601283 |
| DOI: | 10.1016/j.annonc.2022.07.1144 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1018P -- Source: Wos |
